Drug intelligence / Profile preview

AllerVarx

Development stage: Unknown
Lead developer: NTC Pharma
Administration: Oral

Overview

AllerVarx, also known as Lertal in Europe, is a patented Natural Health Product developed by NTC s.r.l. and exclusively in-licensed by Innovus Pharma for the U.S. and Canadian markets. It is indicated for the alleviation of symptoms associated with allergic rhinitis.

Brand names: AllerVarxLertal

Beyond the preview

Go deeper on AllerVarx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AllerVarx.

Explore the full profile